Answers are grounded in this paper and cite their sources.
ECF is a highly active regimen with acceptable toxicity in patients with esophagogastric adenocarcinoma. In a proportion of patients with LAD, chemotherapy enabled potentially curative surgery to be performed. The results justify further investigation of this regimen in a neoadjuvant setting.
No takes yet. Share an insight, caveat, or question.
Bamias et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: